Introducing Galleri multi-cancer early detection test

Galleri is a proactive blood test that can be done annually, screening for many aggressive cancers before symptoms appear.1,2,3

Check Eligibility & Request the Test

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

Patient Story: Roger, Cancer Signal Detected with the Galleri test

Patient Story: Roger, Cancer Signal Detected with the Galleri test

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri test, a multi-cancer early detection test serviced by GRAIL, is available at no cost to eligible non union employees and their dependents ages 40-49 with risk factors and 50 years and older enrolled in a Lennox UMR medical plan.

Non Union Employees4

  • Enrolled in a Lennox UMR medical plan
  • 50 years and older
  • Ages 40 to 49 with additional risk factors
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 5 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

* excludes basal or squamous cell carcinoma of the skin

** excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

Please note that the Galleri test is not available for people who are currently pregnant.

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Dependents / spouses4

  • Enrolled in a Lennox UMR medical plan
  • 50 years and older
  • Ages 40 to 49 with additional risk factors
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 5 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

* excludes basal or squamous cell carcinoma of the skin

** excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

Please note that the Galleri test is not available for people who are currently pregnant.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Note to dependents: Use the employee’s insurance information when requesting the test. Use your personal information to request the test.

While individuals ages 40-49 with certain risk factors may be at an elevated risk for cancer, Galleri was only studied in a population age 50 and older.5

Our testing process

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 10 minutes. Use your employer Insurance information to start an online health questionnaire about your medical history. Galleri is available by prescription only. By requesting the test and completing the questionnaire, you're requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes Galleri, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your results are ready - about 2 weeks after your blood is received at the GRAIL laboratory.

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Jackie

    Patient testimonial: Jackie

    Cancer Signal Detected

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected

  • Oncologist perspective

    Oncologist Perspectives

1 / 12

Frequently Asked Questions

The Galleri test, a multi-cancer early detection test serviced by GRAIL, is available at no cost to eligible non union employees and their dependents ages 40-49 with risk factors and 50 years and older enrolled in a Lennox UMR medical plan.

To access the Galleri test as a covered benefit, you must request the test through this webpage. 

When requesting through this website, an independent telemedicine healthcare provider will review your request and order the test if appropriate. The test is available by prescription only.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit at no cost to eligible employees and dependents.

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you at Galleri.com/schedule.

Please have your UMR insurance card ready.

  • Enter your name, Group Number, and ID Number exactly as they are displayed on your insurance card. Only Group IDs listed in the drop-down are eligible through Lennox’s benefit.
  • Group ID is listed as Group Number on your card and ID Number is listed as ID on your card.

If you are not eligible for the benefit under Lennox program, you may be able to use pre-tax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test on galleri.com. Check with your FSA or HSA administrator or insurance provider to determine eligibility.

GRAIL is a healthcare company focused on improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL or Galleri about your benefit or the Galleri test.

Recuro Health is an independent telemedicine, nationwide care provider, supporting virtual physician consultations related to receiving the Galleri test. A Recuro Health physician will review your test request and order the test, if appropriate. A Recuro Health provider will also share your test result with you.

Under the Lennox benefit program, employees and dependents are eligible for benefit coverage of the Galleri test every 12 months from the date of of the last Galleri test.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent telemedicine provider will review your request and order the test, if appropriate.

The Galleri test is provided at no cost to eligible employees and dependents only when obtained through this authorized site https://www.Galleri.com/Lennox.

The blood draw associated with Galleri must occur on a date you are covered under this employee benefit.

Employees are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after Lennox benefit coverage has ended.

Your individual Galleri test result is confidential and will not be shared with your employer. Your employer only receives de-identified and aggregated information across all employees (for example, how many tests have been requested). 

Segments of personal information may be used, as allowable by HIPAA, for clerical activities such as payment and operations purposes. This information is carefully handled in accordance with privacy regulations to ensure your data remains protected.

If after taking the Galleri test, you receive a bill with out-of-pocket responsibilities from your health insurer please contact the GRAIL Billing Support Team at (833) 694‑2553 and select option two (Billing) for assistance. Our team will discuss how we may assist. 

Additionally, financial assistance is available for eligible patients who are uninsured and may be available for insured patients unable to pay the out-of-pocket amount determined by their insurance.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit at no cost to eligible employees and dependents. An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you at Galleri.com/schedule.

The blood draw associated with Galleri must occur on a date you are covered under this employee benefit. 

Employees are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after Lennox benefit coverage has ended. In the event of a Galleri Cancer Signal Detected test result, the program does not cover or pay for follow-up consults and diagnostic procedures (e.g., imaging, biopsies, other laboratory tests, etc.) that your healthcare provider may recommend. You may incur cost-share expenses such as co-pays, deductibles, and co-insurance. Please contact your health insurance member services via the phone number listed on the back of your health insurance card to determine covered expenses and your potential costs related to these recommended follow-up procedures.

Before proceeding to checkout, you should check the box to schedule a pre-test consultation with an independent telemedicine provider. This step will allow you to ask any questions such as about your risk and family history.

Galleri is a multi-cancer early detection test that can be taken as a simple annual blood test and screens for many of the deadliest cancers before they become symptomatic. The Galleri test gives you more control when it comes to cancer. 

In a clinical study, the Galleri test was able to detect a signal shared by more than 50 types of cancer.3 See the list of cancer types study participants had when a cancer signal was detected.

Watch a short video to learn more

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancers growing in the body shed DNA into the bloodstream.3,6,7 Although there are many types of cancer, the DNA fragments can act like a unique “fingerprint” of cancer. This Galleri test screens for many of the deadliest cancers before they become symptomatic, including those without recommended screening tests.1,3 When there is a Cancer Signal Detected, the results also provide predicted Cancer Signal Origin to help your healthcare provider determine the next steps for diagnosis. 

*In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with Cancer Signal Detected test result. 

Watch a short video to learn more

More than 1 in 3 people will develop cancer in their lifetime.8 People over the age of 50 have a 13 times higher risk for cancer than those under 50. Cancer risk increases for everyone as they age, regardless of family history9 — only 5% to 10% of cancers are inherited.9,10 

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. Talk to your provider about your risk for cancer, and whether the Galleri test is right for you. 

Learn more about cancer risk

In a clinical study, Galleri detected a signal shared by over 50 types of cancer —including some fast-spreading and aggressive cancers responsible for approximately two-thirds of cancer deaths.3 Galleri is a cancer screening test, meaning it looks for cancer before symptoms appear. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. 

See the list of cancer types study participants had when a cancer signal was detected.3 

False positive and false negative results do occur.

Nearly 99% of people who take the Galleri test will receive a No Cancer Signal Detected result. A Cancer Signal Detected result is expected in approximately 1% of Galleri tests in people over 50 years of age. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.5 

Some of the ways we measure test accuracy is with positive predictive value (PPV) and a false positive rate. A PPV is the probability that a person with a Cancer Signal Detected test result has cancer. In a recent study the PPV was 43.1% for study participants with a Cancer Signal Detected result who were diagnosed with cancer. The false positive rate was 0.5% for participants without cancer.5

No, a genetic or hereditary risk assessment is a one time only measurement and assesses your future risk of developing cancer. The Galleri test is a point-in-time test that identifies DNA in the bloodstream shed by cancer cells and screens for cancer at the time of testing.

The test is only available in the US at this time.

Schedule a time and place convenient for you. Visit: Galleri.com/schedule to select either

  • A partner lab

  • A mobile phlebotomy option.

    • A trained technician will come to your home, office, or any preferred location to complete your blood draw

Learn more about how your sample is processed at the GRAIL laboratory by watching this video.

Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample.

Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.

To schedule your blood draw visit: Galleri.com/schedule

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing. Everything needed to complete the blood and return the sample is within the Galleri kit.

If you or your blood draw technician has questions, please call Customer Service: (833) 694‑2553.

No, fasting is not required for the Galleri test.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes from a vein in your arm.

If you no longer wish to receive your Galleri results, contact GRAIL Customer Service by calling (833) 694‑2553.

Your sample will arrive at the GRAIL lab one to two days after your blood draw. Test results will be available about two weeks after your sample is received at the GRAIL lab.

If you participated in an onsite blood draw sponsored by your employer results may take as long as three weeks.

Your test results can be requested by contacting GRAIL Customer Service by calling (833) 694‑2553.

The Galleri test detected DNA methylation patterns that are often associated with cancer in your blood sample. About 1 out of every 100 tests has a Cancer Signal Detected result.5 

This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a Cancer Signal Origin. This helps your doctor determine the next steps for diagnosis. 

Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps. 

False positive results do occur.

The Galleri test looked for a cancer signal in your blood sample and did not find one. This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Continue with routine cancer screenings your healthcare provider recommends. 

A Galleri result of No Cancer Signal Detected does not rule out cancer.

The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Using Galleri in addition to recommended single-cancer screenings can increase your chances of detecting cancer early, to allow for earlier treatment. 

Galleri does not detect a signal for all cancers and not all cancers can be detected in the blood.

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

All results are automatically shared with the provider who ordered the test. When requesting the test, you may provide the information for your primary care provider. If you would like us to fax your results to an additional healthcare provider, please contact Customer Service by calling (833) 694‑2553 to receive instructions on how to complete a results release form.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. American Cancer Society Cancer Facts and Figures 2023. Available at: https://www.cancer.org/content/... GRAIL, Inc. Data on file GA-2021-0065
  3. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  4. Christine Clark Dur, Margaret McCusker. Evaluation of factors associated with elevated cancer risk among persons under age 50. GRAIL, LLC. Data on File GR-2023-0098
  5. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi:10.1016/S0140-6736(23)01700-2
  6. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Mar 30;31(6):745-59. doi: 10.1016/j.annonc.2020.02.011
  7. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016 Jul 8;35:347–76. doi: 10.1007/s10555-016-9629-x
  8. American Cancer Society. Lifetime risk of developing or dying from cancer. [cited 2023 Oct 11]. https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developingor- dying-from-cancer.html
  9. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. [Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.]
  10. NIH, National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. [cited 2023 Mar 3]. https://www.cancer.gov/about-cancer/causesprevention/ genetics/genetic-testing-fact-sheet